GIO Therapeutics
Tilly (Matilda) Bingham is an accomplished scientist with extensive experience in the pharmaceutical industry, currently serving as CSO/COO at GIO Therapeutics since January 2024. Tilly's notable roles include Executive in Residence at Cumulus Oncology, Executive Committee Member for the European Federation for Medicinal Chemistry and Chemical Biology, and Editor for Progress in Medicinal Chemistry at Elsevier. Previously, Tilly held leadership positions at Concept Life Sciences, including Chief Scientific Officer and Director of the Integrated Drug Discovery Group. Tilly also significantly contributed at Redx Pharma as Head of Research and Operations, focusing on strategic alignment and operational leadership across various research portfolios. Tilly earned a Ph.D. in Organic Chemistry from UCL and a BSc in Chemistry from Imperial College London.
This person is not in any teams
This person is not in any offices
GIO Therapeutics
GIO Therapeutics stands at the forefront of medical innovation, specialising in the development of G protein-coupled receptor (GPCR)-targeted pharmaceuticals. Recent scientific research has highlighted the crucial role of GPCRs as membrane receptors within the tumour microenvironment where their role significantly impacts intercellular signalling. This discovery has produced a new pool of potential therapeutic targets, which are now becoming accessible thanks to advanced structure-based drug design techniques. Our innovative approach positions us to address complex challenges in oncology and inflammatory diseases. Each member of the GIO team brings a unique set of skills and experiences, all united by a shared passion for drug discovery and a history of building and creating successful companies. At GIO Therapeutics, we believe in the power of collaboration to drive innovation and achieve groundbreaking results in oncology. We welcome like-minded organisation and professionals to get in touch. GIO Therapeutics is a proud venture of Cumulus Oncology.